Ipamorelin Peptide

Product Specifications

• CAS: 170851-70-4
• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
• Molecular Formula: C₃₈H₄₉N₉O₅
• Molecular Weight: 711.85 Da
• Purity: 99%+ (verified by HPLC)
• Appearance: White to off-white lyophilized powder

Storage

Ipamorelin vials must be stored in a cool, dry place away from direct sunlight. Unreconstituted ipamorelin peptide should be kept at -20°C for long-term storage or 2-8°C for short-term storage. Once reconstituted with bacteriostatic water, ipamorelin should be refrigerated at 2-8°C and used within 28-30 days for optimal stability. Do not freeze reconstituted solutions. Always follow proper aseptic technique and storage guidelines to maintain product integrity for research applications.

Solubility

Ipamorelin is freely soluble in bacteriostatic water and sterile saline. Gently swirl the vial after adding solvent. Do not vortex or shake vigorously, as this may damage the peptide structure.

Intended Use

Ipamorelin is intended for research purposes only and is not approved for human use.

Ipamorelin Peptide Benefits: Selective GH Release Without Cortisol Elevation

• Ipamorelin acts via the GHS-R (ghrelin receptor / growth hormone secretagogue receptor) to trigger pulsatile GH release that closely mirrors natural secretion patterns. Its selectivity for GH over other pituitary hormones is the most studied and significant characteristic of the ipamorelin peptide.
• Landmark preclinical research confirmed that ipamorelin produced a dose-dependent GH pulse in rats comparable in magnitude to GHRP-6 and GHRP-2, while causing no statistically significant increase in ACTH, cortisol, aldosterone, or prolactin even at doses up to 500 mcg/kg body weight.
• Ipamorelin side effects in preclinical models have been notably limited compared to other GHRPs. The absence of cortisol and prolactin elevation distinguishes it from earlier secretagogues and makes it a subject of interest for long-duration research protocols.

CJC-1295 Ipamorelin: Synergistic Growth Hormone Release Research

• The CJC-1295 ipamorelin combination is one of the most researched GHRP/GHRH pairings in preclinical GH science. CJC 1295 acts on the GHRH receptor while ipamorelin acts on the GHS-R, meaning co-administration simultaneously stimulates the somatotropic axis from two distinct and complementary receptor targets.
• Research on GHRP and GHRH co-administration demonstrates a synergistic GH release that substantially exceeds what either compound produces independently. The dual-receptor mechanism underpins the scientific rationale for the CJC 1295 ipamorelin combination in modern peptide research.
• CJC 1295 ipamorelin dosage in preclinical research typically employs matched concentrations of both peptides administered together via subcutaneous injection, targeting GH secretion, body composition, and recovery endpoints.

Ipamorelin Benefits for Bone Growth and Body Composition

• Preclinical studies in young rats show ipamorelin significantly stimulates longitudinal bone growth in a dose-dependent manner, producing measurable increases in tibia length and body weight over 2-week research periods. Effects are mediated through downstream GH and IGF-1 signaling.
• Ipamorelin peptide benefits in body composition research include increases in lean tissue mass consistent with GH-driven anabolic signaling, with growth gains attributed to lean mass increases rather than fat accumulation in treated research subjects.
• Ipamorelin before and after comparisons in controlled preclinical studies show statistically significant improvements in bone mineral content markers and lean mass, positioning the compound as an active area of GH secretagogue and skeletal biology research.

Ipamorelin Dosage for Research

Ipamorelin dosage per day used in preclinical research varies by study design, animal model, and adminisration route. Common protocols in published literature include:

• Subcutaneous injection: 1-10 mcg/kg body weight, once to twice daily, used in bone growth and body composition models.
• Intraperitoneal injection: Comparable dosing used in metabolic and systemic GH secretion studies.

Ipamorelin dosage and timing in research protocols often aligns administration with periods of fasting or rest cycles to maximize GH pulse amplitude, consistent with the natural relationship between feeding state and GH secretion dynamics. A peptide calculator can help scale published mcg/kg doses to a given research subject weight.

CJC-1295 and Ipamorelin Dosage in Combined Research Protocols

When CJC-1295 and ipamorelin are studied together, matched concentrations of both peptides are administered together, leveraging synergistic GH release from their complementary receptor targets, with CJC-1295 acting on the GHRH receptor and ipamorelin acting on the GHS-R (ghrelin receptor).

Research Protocol Notes

This product is intended for research purposes only and should not be used for human consumption. It is strictly designated for laboratory and scientific use by qualified professionals. Common research applications include:

• In vitro cellular assays and cell culture studies
• Receptor binding profiling and signaling pathway analysis
• Analytical reference standards for High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS)
• Approved in vivo animal modeling to investigate physiological mechanisms and metabolic responses